The Advanced Research Projects Agency for Health, the centerpiece of the Biden Administration’s war on disease, is designed to be something much more than an ordinary federal bureaucracy.
President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.”
Now that Joseph R. Biden Jr. is inaugurated and safely ensconced in the White House, cancer groups expect him to pick up where he left off as vice president four years ago—pursuing a sober and ambitious agenda for accelerating progress in cancer research.
On Nov. 15, shortly after midnight, President Donald J. Trump tweeted a link to a New York Post headline:
For the first time in U.S. history, the White House will soon be occupied by a president who has demonstrated a deep understanding of cancer research.
The future of American health care, pandemic response, and sustained funding for cancer research hangs in the balance as the final votes are being counted and legal challenges launched in the 2020 presidential election.
No prizes should be handed out to anyone who predicted that:
As the rancor in Washington continues to escalate from bickering to a war on many fronts, the deadline approaches for the end of a continuing resolution that keeps the federal government open until Jan. 19.
League tables like those published by U.S. News and World Report should probably be taken with a pinch of salt in any case, but it is the self-marketing of these tables that is just a bit problematic.
After a year of trying to understand the biology and politics of cancer, Vice President Joe Biden admits that he has a stronger grasp on the nuts and bolts of Washington than the evolutionary mysteries known collectively as cancer.
